AXIM Biotechnologies, Inc. Stock Other OTC
Equities
AXIM
US05463V1008
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 8.88K | Sales 2023 | 39.52K | Capitalization | 4.52M |
---|---|---|---|---|---|
Net income 2022 | -6M | Net income 2023 | -8M | EV / Sales 2022 | 1,218 x |
Net Debt 2022 | 5.64M | Net Debt 2023 | 5.74M | EV / Sales 2023 | 259 x |
P/E ratio 2022 |
-0.69
x | P/E ratio 2023 |
-0.48
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 71.61% |
Managers | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Robert Malasek
DFI | Director of Finance/CFO | 55 | 16-06-28 |
Kurt Phinney
COO | Chief Operating Officer | - | 23-05-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Huemoeller
CEO | Chief Executive Officer | 68 | - |
Timothy Scott
BRD | Director/Board Member | 71 | 17-05-17 |
Director/Board Member | 76 | 17-05-17 |
1st Jan change | Capi. | |
---|---|---|
+0.76% | 43.84B | |
+5.49% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.45% | 25.53B | |
-25.48% | 18.18B | |
-3.14% | 12.29B | |
+25.89% | 12.29B | |
+6.88% | 11.15B |